| Drug Type Induced pluripotent stem cells (iPSC), CAR-T | 
| Synonyms- | 
| Action inhibitors, modulators | 
| Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators), MICA inhibitors(MHC class I polypeptide-related sequence A inhibitors) + [2] | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Solid tumor | Preclinical | United States  | 10 Nov 2022 | 





